Asia Fresh News

Asia Fresh Stories

Archive for April 2015

LTE Basebands Accounted for Over 50 Percent of Cellular Baseband Revenue in 2014 says Strategy Analytics

leave a comment »

— Qualcomm, MediaTek, Spreadtrum, Marvell and Intel Held the Top-five Revenue Share Spots

BOSTON /PRNewswire/ — The global cellular baseband processor market grew an impressive 14.1 percent year-over-year to reach $22.1 billion in calendar year 2014, according to Strategy Analytics Handset Component Technologies (HCT)  service report, “Baseband Market Share Tracker 2014: Qualcomm, MediaTek and Spreadtrum Capture 80 Percent Volume Share.”

Click here for the report:

Logo –

Based on this research from Strategy Analytics, Qualcomm, MediaTek, Spreadtrum, Marvell and Intel grabbed the top-five baseband revenue share spots in calendar year 2014. Qualcomm finished the year 2014 with 66 percent revenue share, followed by MediaTek with 17 percent revenue share and Spreadtrum with 5 percent revenue share.

According to Sravan Kundojjala, Associate Director, “For the first time on an annual basis, revenue from LTE baseband sales overtook revenue from 3G baseband sales, thanks to a strong push from the industry. Qualcommcontinued to lead this high-growth LTE baseband segment. However, Qualcomm’s LTE baseband competitorsHiSilicon, Intel, Marvell, MediaTek and Samsung made good progress in 2014 and increased their LTE baseband shipments.”

According to Stuart Robinson, Executive Director of the Strategy Analytics Handset Component Technologiesservice, “Despite taking a hit from reduced TD-SCDMA baseband shipments, Spreadtrum registered a ten-fold growth in its W-CDMA baseband shipments and achieved a double-digit share in the global W-CDMA baseband market in 2014. Spreadtrum is well-positioned to increase its W-CDMA and LTE baseband shipments significantly in 2015.”

According to Christopher Taylor, Director of the Strategy Analytics RF and Wireless Component service, “MediaTek ranked number two in the global LTE baseband market for the first time on an annual basis in 2014. Strategy Analytics predicts MediaTek will continue to gain share in LTE basebands, thanks to increased traction in China. Growing revenue contribution from LTE basebands will lift MediaTek’s baseband revenue share over the next few quarters.”

About Strategy Analytics

Strategy Analytics, Inc. provides the competitive edge with advisory services, consulting and actionable market intelligence for emerging technology, mobile and wireless, digital consumer and automotive electronics companies. With offices in North America, Europe and Asia, Strategy Analytics delivers insights for enterprise success.

European Contact: Stuart Robinson, +44(0)-1908-423-637,

US Contact: Christopher Taylor, +1-617-614-0706,

Source: Strategy Analytics

Written by asiafreshnews

April 30, 2015 at 5:53 pm

Posted in Uncategorized

International Business Systems Announces Sessions for 2015 Americas Customer Conference

leave a comment »

— IBS Connect Speakers Include Executives from IBM, McGraw-Hill Education, Dot Foods, MWI Veterinary Supply, and Zwilling J.A. Henckels

FOLSOM, Calif. /PRNewswire/ — International Business Systems (IBS), a global leading integrated ERP, WMS and supply chain solution provider, today announced the companies presenting at its 2015 IBS Connect Americas Customer Conference. The event will take place May 12-14 in Chandler, Ariz., at the Sheraton Wild Horse Pass Resort, where the Super Bowl XLIX-champion New England Patriots stayed and celebrated their victory.

Logo –

IBS, a trusted industry leader of ERP and WMS distribution software, is preferred for consistently improving operational efficiencies and business performance for mid-market companies challenged by the complexities of managing distribution.

IBS Connect Americas – Innovation @ Work – will assemble industry thought leaders for several days of immersion into cutting edge trends, software and issues driving the 21st Century supply chain.

Day one will include user group meetings, which include a deep dive into the IBS product roadmap, an open forum for topics such as key product enhancement areas, the benefits to upgrading, increasing user productivity, gaining supply chain efficiencies and more.

Executives from the following companies will present case studies to encourage group discussions, explore supply chain trends and educate attendees on the future of the IBM iSeries:

  • Dot Foods – John Long, Senior Vice President of Warehousing
  • IBM – Tim Rowe, Business Architect for Application Development for IBM i
  • McGraw-Hill Education – Matthew Cantwell, Vice President, Finance & Strategy
  • MWI Veterinary Supply – Alden Sutherland, Vice President & CIO
  • Zwilling J.A. Henckels – John Henkel, CFO & VP Operations

“We have assembled a group of leading companies from the supply chain industry to impart their knowledge and help our attendees grow their skillsets and productivity,” said Tim Conroy, Americas General Manager, IBS.  “IBS executives will complement these presentations by offering remarks on the state of the industry, and product roadmaps of our IBS Enterprise, Dynaman, S&OP, IBS Analytics powered by QlikView, and Bookmaster product lines.”

Col. Mark Tillman, chosen as the nation’s 12th Presidential pilot and Commander of Air Force One from 2001-2009, will kick-off the event as the conference keynote speaker.

For more information about IBS Connect, use #IBSConnect15 or please visit

About IBS
International Business Systems (IBS) is a leading global integrated ERP, WMS and supply chain distribution software solution provider. For more than 35 years, we have helped customers such as WORLDPAC, Fidelitone, Associated Pharmacies, Inc., GILLIG, Zwilling J.A. Henckels, Miele Inc., Tri Literal LLC, Mighty Auto Parts, Victory Packaging Inc. and many more streamline, automate and accelerate their distribution network processes, and drive profitability and efficiency.

For more information, please visit or contact:

Philip Anast
Tech Image (for IBS)

Source: International Business Systems
Related Links:

Written by asiafreshnews

April 30, 2015 at 5:44 pm

Posted in Uncategorized

Getac Announces Significant Upgrades to Company’s Fastest-Selling F110 Rugged Tablet and V110 Rugged Convertible Notebook

leave a comment »

MELBOURNE, Australia, /PRNewswire/ — Getac Technology Corporation, a leading manufacturer of rugged computers, today released the updated F110 rugged tablet and the updated V110 rugged convertible notebook, making Getac’s fastest-selling products even better, making Getac’s fastest-selling products even better. The second generation F110 and V110 products each feature a fifth generation Intel Processor, Intel HD Graphics 5500, and eight-megapixel rear camera, a front HD webcam and an updated LumiBond 2.0 touch screen that allows glove-on use. Both products will be distributed exclusively by Synnex Australia Pty Ltd. in theAustralia and New Zealand Regions.

“Demand for the F110 rugged tablet and V110 rugged convertible has been incredible,” said Rick Hwang, president of Rugged Solutions Business Unit at Getac. “The F110 quickly became the fastest selling product in Getac history and opened up new vertical markets for us. The size, weight and flexibility of the F110 and the V110 have allowed us to expand into the manufacturing, automotive and healthcare markets while growing our market share in traditional rugged markets, including military, public safety and utilities.”

The F110 is a large-screen rugged tablet that packs superior performance and a large 11.6-inch display into a compact design. The F110 is less than one-inch thick and measures slightly more than 12 x 8 inches in size. At three pounds, this rugged tablet is one of the lightest large-screen, fully rugged tablets ever built.

The V110 is a thin and light rugged convertible that measures less than 12 x 9 inches in size, is a mere 1.3 inches thick and weighs slightly more than four pounds. A quick twist of the unique multi-position hinge allows the V110 to effortlessly transform from a laptop to a tablet, giving users the versatility needed in unpredictable environments. The V110 also features a large 11.6-inch display and a full-size, waterproof-membrane backlit keyboard that is 56% larger than the competition’s. Its 88 standard-sized, island-style independent keys provide an unmatched premium feel and increased durability.

Both products incorporate the latest processors: the fifth generation Intel Core i5-5200U (2.2GHz), i5-5300U (2.3GHz with vPro Technology), i7-5500U (2.4GHz) or i7-5600U (2.6GHz with vPro Technology), together known as the Broadwell platform, which are designed for speed and efficiency. The i5 and i7 CPUs feature Intel Turbo Boost Technology, clocking maximum speeds up to 2.7GHz, 2.9GHz, 3GHz and 3.2GHz, respectively. In addition, the new Intel HD 5500 graphics provide an unparalleled level of responsiveness and frame rate for both 2D and 3D graphics.

One of the most useful features is also one of the simplest. Both the F110 and the V110 feature dual hot-swappable batteries that allow for endless power by simply “swapping” in a fresh battery without needing to shut down applications or the operating system. Each V110 set of batteries provide up to 13 hours of operation, and the F110 battery set provides up to 12 hours of operation.

The F110 and the V110 can be ordered with built-in multi-carrier 4G LTE on a single chip. Additionally, for vehicle deployment use, three pass-through antenna ports can be added, allowing customers to simultaneously connect high-gain GPS, WWAN and WLAN roof-mounted antennae.

With the revolutionary LumiBond® 2.0 technology that bonds the display glass with the touch panel and LCD, Getac has created a single pane that is more durable and improves readability with its wide viewing angle. This creates a display that is more readable and offers better contrast and more crisp colors than a typical rugged laptop display. The LumiBond 2.0 adds the flexibility to configure the display for use while wearing gloves or with direct exposure to rain—essential features when operating in inclement weather or working near hazardous materials when gloves are required.

The new F110 rugged tablet and V110 convertible rugged notebook  will be available for sale in Australia andNew Zealand with an RRP starting at AU$3,439 and AU$4,719 respectively. If you are interested in our products or you would like to become an authorized Getac Partner, or require detailed information please visit: or contact your Synnex Account Manager on 1300 100 104.

About Getac

Getac is a key subsidiary of MiTAC-Synnex Business Group (2014 consolidated revenue $29.4 billion USD). Getac was established in 1989 as a joint venture with GE Aerospace to supply defense electronic products. Today, Getac’s business includes rugged notebooks, rugged tablets, rugged handheld and mobile video systemdevices for military, police, fire, utility, insurance and field-service customers. For more information, visit


Irene Sun

Source: Getac Technology Corporation
Related Links:

Written by asiafreshnews

April 30, 2015 at 5:12 pm

Posted in Uncategorized

Takeda Agrees to Settle ACTOS Product Liability Lawsuits and Claims; Takeda Stresses Continued Commitment to ACTOS

leave a comment »

DEERFIELD, Ill. /PRNewswire/ — Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that they have reached an agreement expected to resolve the vast majority of ACTOS (pioglitazone HCl) product liability lawsuits pending against Takeda in the U.S. Takeda will take a $2.7 billion charge against earnings in the fourth quarter of fiscal year 2014 to cover the settlement and the costs associated with defending remaining cases and for other related litigation. The settlement will become effective if 95 percent of current litigants and claimants opt into the settlement. Once that threshold is achieved, Takeda will pay $2.37 billion into a settlement fund. However, that figure will rise to$2.4 billion if 97 percent or more of the current litigants and claimants opt to participate in the settlement.

Takeda believes that the claims made in this litigation are without merit and does not admit liability. Takeda believes the company acted responsibly with regard to ACTOS and that ACTOS has a positive benefit/risk profile for the treatment of type 2 diabetes. Takeda’s decision to settle does not change the company’s continued commitment to ACTOS. ACTOS continues to be available as a treatment option in the U.S., Japan and other countries. Pioglitazone has been approved for use in 95 countries, including the U.S., Japan, several in Europe,Australia, Brazil, Canada and Russia, to highlight a few.

The settlement will reduce financial uncertainties for the company and provides a significant degree of assurance toward resolving a high percentage of the ACTOS product liability claims. The settlement allows the company to fully focus on developing innovative medicines for patients around the world.

Under the settlement, current litigants and claimants who meet prescribed criteria would receive payouts from the fund. The settlement will not affect Takeda’s ability to pay dividends.

Takeda stands behind the substantial data that confirm a positive benefit/risk profile for ACTOS, which includes more than 14 years of clinical and patient experience with the product.

Indication for ACTOS

ACTOS (pioglitazone) is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for the treatment of type 1 “juvenile” diabetes or diabetic ketoacidosis (increased ketones in blood or urine).

Important Safety Information


ACTOS can cause or worsen heart failure. ACTOS can cause the body to keep extra fluid (fluid retention), which leads to swelling (edema) and weight gain. Extra body fluid can make some heart problems worse or lead to heart failure. Heart failure means the heart does not pump blood well enough. Patients should not take ACTOS if they have severe heart failure. If patients have heart failure with symptoms such as shortness of breath or swelling, even if these symptoms are not severe, ACTOS may not be right for them. Patients should call their doctor right away if they experience swelling or fluid retention (especially in the ankles or legs), shortness of breath or trouble breathing (especially when lying down), an unusually fast increase in weight, or unusual tiredness.

ACTOS may not be right for everyone. Serious side effects may happen to people taking ACTOS.

Patients should not take ACTOS if they are allergic to any of its ingredients.

ACTOS may cause liver problems. Patients should call their doctor right away if they experience nausea, vomiting, stomach pain, unusual or unexplained tiredness, loss of appetite, dark urine, or yellowing of the skin or eyes, as these could be symptoms of liver damage.

Women are at higher risk of having broken bones (fractures) while taking ACTOS.

There may be an increased chance of having bladder cancer when patients take ACTOS. Patients should not take ACTOS if they are receiving treatment for bladder cancer. Patients should tell their doctor right away if they have blood or a red color in the urine, have an increased need to urinate, or have pain while they urinate, as these may be symptoms of bladder cancer.

When taking ACTOS with insulin or other anti-diabetic medications (especially sulfonylureas), hypoglycemia (low blood sugar) may occur. Lightheadedness, shakiness, dizziness, or hunger may mean that a patient’s blood sugar is too low. Patients should talk to their doctor if low blood sugar is a problem for them.

Some patients have experienced visual changes while taking ACTOS. If patients experience vision problems, patients should consult their doctor immediately. Patients should have their eyes checked regularly.

If a woman is of childbearing age, but does not have monthly periods, she should talk to her doctor before taking ACTOS, as it could increase her chance of becoming pregnant.

It is not known if ACTOS can harm an unborn or nursing baby. Patients should talk to their doctor if they are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed.

Adverse Reactions

The most common side effects (>5%) of ACTOS include cold-like symptoms, headache, sinus infection, muscle pain, and sore throat.

Drug Interactions

Patients should tell their doctor about all the medicines, vitamins, and supplements they take. ACTOS and some other medicines can affect each other. Patients may need to have their dose of ACTOS or certain other medicines changed.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. or call 1-800-FDA-1088.

Please see the accompanying Complete Prescribing Information and Medication Guide for ACTOS.

About Takeda Pharmaceuticals U.S.A., Inc. and Takeda Development Center Americas, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals U.S.A., Inc. and Takeda Development Center Americas, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit

This press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda’s plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “should,” “anticipate,” “plan,” “assume,” “continue,” “seek,” “pro forma,” “potential,” “target,” “forecast,” “guidance,” “outlook” or “intend” or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda’s business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressures and developments; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.

Source: Takeda Pharmaceuticals U.S.A., Inc.
Related Links:

Written by asiafreshnews

April 30, 2015 at 5:06 pm

Posted in Uncategorized

ASX-Listed Holista CollTech Brings Revolutionary Injection-Free “Botox-Like” Geltox Skin Science to Asia Pacific

leave a comment »

-To Develop Cosmetic Range Based on Proprietary Sheep Collagen

KUALA LUMPUR, Malaysia /PRNewswire/ — Australian-listed Holista CollTech Ltd (“Holista”; ASX: HCT) said today that it has secured Asia Pacific distribution rights for Geltox Skin Science, a breakthrough solution that produces a “botox-like” effect to reduce or remove skin wrinkles using plant extracts  without the need for injections.

Geltox Skin Science has developed tiny water- and fat-soluble liposomes that can penetrate the skin. The liposomes coat and transport anti-ageing active ingredients that increase efficiency and lower toxicity of the encapsulated ingredients which, after penetration, are absorbed and diffused better in the body  minus the pain and hassle of syringes and needles requiring qualified professionals.

Developed by Spain-based Palma Biotech, patent-pending Geltox Skin Science uses a combination of plant-based peptides to cause mild paralysis in specific muscles reducing facial expression lines including frowns. Similar to Botox®, the effects are immediate upon application and, over time, remove the lines altogether  except injection is no longer required.

Palma Biotech, a specialist in liposomes and liposomal encapsulation technologies, works with different active compounds that can be paired with its Liposome expertise. Holista, which distributes supplements, natural ingredients and wellness products, has developed and patented its own sheep collagen. Along with the distribution rights, Holista intends to collaborate with Geltox Skin Science to develop sheep collagen liposomes for cosmetic applications.

“Geltox Skin Science is a breakthrough technology which has many applications for cosmetics and even medical use. By eradicating the need for injections, it offers a pain-free alternative which will gain wide acceptance across the region, including younger men and women. Beyond our existing range of sheep collagen, we now have a new avenue of growth with a unique technology,” said Dr. Rajen Manicka, CEO of Holista which is headquartered in Kuala Lumpur, Malaysia.

Mr. Frode Thengs-Vik, the CEO and Co-Founder of Palma Biotech, said, “The product is registered, approved and used in Europe. It is manufactured as per standards of the European Union.”

“We are pleased to have found an Australian partner that can take our unique innovation to the Asian Pacific region which is now one of the most dynamic markets in the world,” said Mr. Olav Hellebo, Chairman of the Board and Co-Founder of Palma Biotech.

Business Enquiries:

Media Enquiries:
WeR1 Consultants
Ms. Sheryl Sim;

Source: Holista Colltech

Related stocks: Australia:HCT

Written by asiafreshnews

April 30, 2015 at 4:10 pm

Posted in Uncategorized

New Appointment To The Red Flag Group Management

leave a comment »

-Peter Connor has joined The Red Flag Group as Vice President of Products to further advance the firm’s products portfolio.

SAN FRANCISCO /PRNewswire/ — Leading integrity and compliance risk management firm The Red Flag Group is strengthening its Leadership Team with the appointment of industry veteran Peter Connor as Vice President of its Products Group.

Peter Connor
Peter Connor

The Red Flag Group focuses on identifying integrity and compliance risks and then managing those risks. A pioneer in the compliance industry, the firm has built third-party compliance programmes for over 800 global companies.

Once a client of The Red Flag Group in his previous role as Chief Compliance Officer of IT giant Citrix Systems, Peter will be leading the Products Group.

“I engaged with The Red Flag Group as a client because they have a talented and global team that really understood my desire to implement creative, cost-effective approaches to compliance problems,” said Peter. “In my new role with the firm, I plan to extend the range of exceptional products and services, which I know our clients are going to love.”

Peter will ensure that the group continues to deliver the best due diligence products in the industry, aided by practical and effective technology solutions with sophisticated advisory services. Together, these will support clients’ every need in the compliance space and improve their integrity profiles, creating value for their businesses.

Peter has over 30 years of international legal and compliance experience. At Citrix, he was responsible for developing the anti-bribery, antitrust and data-privacy programmes and redesigning the company’s compliance training programmes. As well as working for Citrix, Peter also previously worked with leading international law firm Baker & McKenzie and with Sun Microsystems in regional general counsel roles based in Hong Kong,California, the United Kingdom and Switzerland.

The Red Flag Group’s CEO David Youngson has been invested in strengthening the leadership of the firm, and shares his satisfaction regarding Peter joining the team: “The recent appointment of Peter Connor as Vice President of Products is the latest hire to our Leadership Team. Peter brings over 30 years of commercial experience and, most importantly, the ‘voice of the customer’ to ensure our product-development roadmaps are aligned with the compliance community’s needs.”

Note to editors:

The Red Flag Group is a global integrity and compliance risk firm. We apply our unique set of advice, technology and business intelligence applications to manage the integrity and compliance risks of our customers. We have a proven methodology that we use to help companies manage these risks.

For more information on The Red Flag Group, please click here

Photo –
Logo –

Source: The Red Flag Group (Consulting) Limited

Written by asiafreshnews

April 30, 2015 at 3:55 pm

Posted in Uncategorized

RS Components Extends 3D Modelling Portfolio with Award-winning SCANIFY(R) Handheld Scanner from Fuel3D

leave a comment »

-Affordable high-resolution, 3D scanning, in colour, for 3D printing, education and hobbyist applications

BEIJING /PRNewswire/ — RS Components (RS), the trading brand ofElectrocomponents plc (LSE:ECM), the global distributor for engineers, has added the CES award-winning SCANIFY® handheld scanner from Fuel3D to its range of affordable desktop systems for 3D digitisation and printing.

RS Components extends 3D modelling portfolio with award-winning SCANIFY® handheld scanner from Fuel3D
RS Components extends 3D modelling portfolio with award-winning SCANIFY® handheld scanner from Fuel3D

SCANIFY uses an innovative combination of stereoscopy and photometry to create an accurate, high-resolution digital model including 8-bit RGB colour data. Setting a new benchmark for affordability among high-performing handheld 3D scanners, SCANIFY is fast, versatile and easy to use. The user places an optical tracking target on the object, as a reference for movement correction, and a one-click shot (0.1 seconds) then captures all the images needed to create the model.

The scanner exports various file formats including STL, as used by many 3D printers, thereby allowing scanned objects to be replicated quickly and easily. In addition, support for OBJ and PLY formats allows direct export to popular design or animation software environments, hence making numerous creative avenues accessible for users such as designers, artists, educators, makers and hobbyists.

RS is among the first distributors to offer SCANIFY to the market, following its launch at CES 2015 in January. The state-of-the-art product won the 2015 CES Best of Innovation Award in the 3D Printing & Additive Manufacturing category for its manufacturer, Fuel3D; a well-funded startup, established to commercialise technology developed at Oxford University in the UK.

SCANIFY joins the rapidly growing portfolio of 3D scanners, printers and printing materials from various manufacturers such as 3D Systems, BeeVeryCreative, MakerBot, RepRapPro, Ultimaker, and the own-brand IdeaWerk FDM printer, now available from RS.

About RS Components

RS Components and Allied Electronics are the trading brands of Electrocomponents plc, the global distributor for engineers. With operations in 32 countries, we offer around 500,000 products through the internet, catalogues and at trade counters to over one million customers, shipping more than 44,000 parcels a day. Our products, sourced from 2,500 leading suppliers, include semiconductors, interconnect, passives and electromechanical, automation and control, electrical, test and measurement, tools and consumables.

Electrocomponents is listed on the London Stock Exchange and in the last financial year ended 31 March 2014had revenues of GBP1.27bn.

For more information, please visit the website at

About Fuel3D

Fuel3D is a developer of advanced 3D scanning systems and solutions. Originally developed for the medical imaging sector, the Fuel3D technology has been adapted for the broader 3D market, with the goal of bringing the benefits of point-and-shoot 3D imaging to consumers, professionals and businesses.

Since raising more than $300,000 and generating worldwide attention through its successful Kickstarter campaign in 2013, the company has gone from strength to strength, raising millions in private investment and signing retail and distribution partners across the world.

Based on technology developed by Professor Ron Daniel, Lecturer in Engineering Science at Oxford University, Fuel3D is today led by Stuart Mead, CEO, a veteran of several successful global technology ventures, and supported by an expert team of hardware and software engineers and scientists. For more information,

RS Components
Tan Soo Chun
Public Relations Manager – Asia Pacific
Telephone: +65-6391-5745

Edelman Public Relations (Singapore)
Yvette Yeo
Telephone: +65-6347-2355

Further information is available via these links:

@RSElectronics; @alliedelec; @designsparkRS

RS Components on Linkedin

RS Components on Weibo

Relevant Links:

Electrocomponents plc

RS Components


Photo –
Logo –

Source: RS Components Singapore

Related stocks: LSE:ECM OTC-PINK:EENEY

Written by asiafreshnews

April 30, 2015 at 2:48 pm

Posted in Uncategorized